Serum ACE as a prognostic biomarker in COVID-19: A Case series

We have earlier proposed that serum ACE (s‐ACE) could be used as a biomarker for severity in COVID‐19 due to an assumed inverse relationship between ACE and ACE2. High s‐ACE could indicate lower ACE2 activity and therefore more widespread and severe SARS‐CoV2 infection, owing to virally mediated dow...

Full description

Saved in:
Bibliographic Details
Published inAPMIS : acta pathologica, microbiologica et immunologica Scandinavica
Main Authors Kolberg, Espen Skarstein, Tonby, Kristian, Wickstrøm, Kristin, Riise, Anne Margarita Dyrhol, Holten, Aleksander Rygh, Amundsen, Erik Koldberg
Format Journal Article
LanguageNorwegian
Published 2020
Online AccessGet full text

Cover

More Information
Summary:We have earlier proposed that serum ACE (s‐ACE) could be used as a biomarker for severity in COVID‐19 due to an assumed inverse relationship between ACE and ACE2. High s‐ACE could indicate lower ACE2 activity and therefore more widespread and severe SARS‐CoV2 infection, owing to virally mediated downregulation of ACE2 (1). Dysregulation of the Renin‐Angiotensin‐Aldosterone system (RAAS) are found in comorbidities known as risk factors for increased morbidity and mortality, such as hypertension and cardiovascular disease (2).
ISSN:0903-4641
1600-0463